Review articles

Advances in the study on Ang/Tie signaling pathway in diagnosis and treatment of sepsis

Expand
  • Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

Received date: 2023-05-01

  Online published: 2024-05-30

Abstract

Sepsis and concomitant multiorgan dysfunction are a group of common clinical syndromes, and their prevalence are increasing year by year due to the increase of the aging population. It reveals that 20 million cases of sepsis occur globally every year, with a mortality rate of 26%. Early diagnosis of sepsis facilitates the adoption of timely and targeted therapeutic strategies, which is a key element in reducing mortality. Endothelial cells (EC) are the early targets of exogenous pathogens and endogenous injury signals, and numerous studies suggest that structural changes and functional activation of EC play an important role in the development of sepsis. As an endothelial-exclusive signaling pathway, the angiopoietin (Ang)/tyrosine kinase receptor (Tie) signaling pathway plays an important role in the abnormal activation and injury of EC, and plays a central role in the regulation of dysfunctional changes in the disease process. The Ang/Tie signaling pathway mainly includes two tyrosine kinase receptors (Tie1, Tie2) located in EC and four secreted glycoprotein ligands (Ang-1, Ang-2, Ang-3, Ang-4). Ang-1 sustainably activates the Tie2 receptor, maintaining function between cells, and between cell and matrix, supporting the normal physiological functions of vascular EC. Ang-2 is an Ang-1 antagonist, competitively blocking the binding of Ang-1 to the Tie2 receptor. In a sepsis environment, the ratio of Ang-1/Ang-2 decreases (Ang-1 decreases, while Ang-2 increases). Ang-2 competitively blocks the binding of Ang-1 to Tie2 receptors, resulting in severe abnormal activation of EC. Ang-2 mediates the release of heparinase (HPSE), resulting in glycocalyx damage and an increase of vascular permeability. Ang-2 increase may promote inflammatory response. Ang/Tie signaling system dysfunction results in coagulation dysfunction, and Ang-2 elevation is a sentinel event in disseminated intravascular coagulation. In terms of disease monitoring, the sensitivity of Ang-2>5.61 ng/mL for diagnosing sepsis is 74.36%. Continuing rise of Ang-2 indicates that patients are in difficulty with restoring endothelial function and normal function in organs. Early dynamic mornitoring of Ang-2 can be used to predict sepsis related lung injury and acute kidney injury. The increase in Ang-2/Ang-1 ratio and Ang-2/soluble Tie ratio are independently correlated with the 90 d- mortality rate of sepsis patients(area under ROC curve is 0.787 and 0.704, respectively). Decrease of Ang-2 and / or Tie-2 in levels indicates good efficay of plasma exchange in sepsis patients. Targeting the Ang/Tie signaling pathway have achieved certain success in animal experiments, but currently clinical trials have not yielded valuable results. Further in-depth research is needed on the Ang/Tie signaling pathway related to sepsis.

Cite this article

YANG Hang, DAI Jing, WANG Xuefeng . Advances in the study on Ang/Tie signaling pathway in diagnosis and treatment of sepsis[J]. Journal of Diagnostics Concepts & Practice, 2024 , 23(01) : 90 -95 . DOI: 10.16150/j.1671-2870.2024.01.012

References

[1] PURCAREA A, SOVAILA S. Sepsis, a 2020 review for the internistJ[J]. Rom J Intern Med, 2020, 58(3):129-137.
[2] SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)[J]. JAMA, 2016, 315(8):801-810.
[3] KORHONEN E A, LAMPINEN A, GIRI H, et al. Tie1 controls angiopoietin function in vascular remodeling and inflammation[J]. J Clin Invest, 2016, 126(9):3495-3510.
[4] TEICHERT M, MILDE L, HOLM A, et al. Pericyte-expressed Tie2 controls angiogenesis and vessel maturation[J]. Nat Commun, 2017, 8:16106.
[5] BRAUN L J, ZINNHARDT M, VOCKEL M, et al. VE-PTP inhibition stabilizes endothelial junctions by activa-ting FGD5[J]. EMBO Rep, 2019, 20(7):e47046.
[6] LEE S J, LEE C K, KANG S, et al. Angiopoietin-2 exa-cerbates cardiac hypoxia and inflammation after myocardial infarction[J]. J Clin Invest, 2018, 128(11):5018-5033.
[7] SALIMI U, MENDEN H L, MABRY S M, et al. Angiopoie-tin-1 protects against endotoxin-induced neonatal lung injury and alveolar simplification in mice[J]. Pediatr Res, 2022, 91(6):1405-1415.
[8] ATREYA M R, CVIJANOVICH N Z, FITZGERALD J C, et al. Detrimental effects of PCSK9 loss-of-function in the pediatric host response to sepsis are mediated through independent influence on Angiopoietin-1[J]. Crit Care, 2023, 27(1):250.
[9] YUAN H T, KHANKIN E V, KARUMANCHI S A, et al. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium[J]. Mol Cell Biol, 2009, 29(8):2011-2022.
[10] ZIEGLER T, HORSTKOTTE J, SCHWAB C, et al. Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J Clin Invest, 2013, 123(8):3436-3445.
[11] RICHTER R P, ASHTEKAR A R, ZHENG L, et al. Glycocalyx heparan sulfate cleavage promotes endothelial cell angiopoietin-2 expression by impairing shear stress-related AMPK/FoxO1 signaling[J]. JCI Insight, 2022, 7(15):e155010.
[12] LUKASZ A, HILLGRUBER C, OBERLEITHNER H, et al. Endothelial glycocalyx breakdown is mediated by angiopoietin-2[J]. Cardiovasc Res, 2017, 113(6):671-680.
[13] DROST C C, ROVAS A, KUSCHE-VIHROG K, et al. Tie2 activation promotes protection and reconstitution of the endothelial glycocalyx in human sepsis[J]. Thromb Haemost, 2019, 119(11):1827-1838.
[14] 付绪哲, 柳英杰, 牛明明, 等. 脓毒症免疫抑制机制的研究进展[J]. 中国临床研究, 2023, 36(5):741-745.
  FU X Z, LIU Y J, NIU M M, et al. Research progress in immunosuppressive mechanism of sepsis[J]. Chin J Clin Res, 2023, 36(5):741-745.
[15] SMADJA D M, GUERIN C L, CHOCRON R, et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients[J]. Angiogenesis, 2020, 23(4):611-620.
[16] FIEDLER U, REISS Y, SCHARPFENECKER M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation[J]. Nat Med, 2006, 12(2):235-239.
[17] LASK A, GUTBIER B, KERSHAW O, et al. Adjunctive therapy with the Tie2 agonist Vasculotide reduces pulmonary permeability in Streptococcus pneumoniae infected and mechanically ventilated mice[J]. Sci Rep, 2022, 12(1):15531.
[18] IDOWU T O, ETZRODT V, SEELIGER B, et al. Identification of specific Tie2 cleavage sites and therapeutic modulation in experimental sepsis[J]. Elife, 2020, 9:e59520.
[19] 闫威威, 董思琴, 汪华学. 红细胞分布宽度与血小板计数比值对脓毒症患者预后的预测价值[J]. 安徽医学, 2022, 43(8):887-891.
  YAN W W, DONG S Q, WANG H X. The predictive value of the ratio of red blood cell distribution width to platelet count for the prognosis of sepsis patients[J]. Anhui Med J, 2022, 43(8):887-891.
[20] HIGGINS S J, DE CEUNYNCK K, KELLUM J A, et al. Tie2 protects the vasculature against thrombus formation in systemic inflammation[J]. J Clin Invest, 2018, 128(4):1471-1484.
[21] SCHMAIER A A, PAJARES HURTADO G M, MANICKAS-HILL Z J, et al. Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19[J]. JCI Insight, 2021, 6(20):e151527.
[22] SZEDERJESI J, ALMASY E, LAZAR A, et al. The Role of Angiopoietine-2 in the Diagnosis and Prognosis of Sepsis[J]. J Crit Care Med (Targu Mures), 2015, 1(1):18-23.
[23] CALFEE C S, JANZ D R, BERNARD G R, et al. Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies[J]. Chest, 2015, 147(6):1539-1548.
[24] RICHTER R P, ZHENG L, ASHTEKAR A R, et al. Associations of Plasma Angiopoietins-1 and -2 and Angiopoie-tin-2/-1 Ratios With Measures of Organ Injury and Clinical Outcomes in Children With Sepsis: A Preliminary Report[J]. Pediatr Crit Care Med, 2020, 21(9):e874-e878.
[25] PRICE D R, BENEDETTI E, HOFFMAN K L, et al. Angiopoietin 2 is associated with vascular necroptosis induction in coronavirus disease 2019 acute respiratory distress syndrome[J]. Am J Pathol, 2022, 192(7):1001-1015.
[26] REILLY J P, WANG F, JONES T K, et al. Plasma angiopoietin-2 as a potential causal marker in sepsis-asso-ciated ARDS development: evidence from Mendelian randomization and mediation analysis[J]. Intensive Care Med, 2018, 44(11):1849-1858.
[27] ROSENBERGER C M, WICK K D, ZHUO H, et al. Early plasma angiopoietin-2 is prognostic for ARDS and morta-lity among critically ill patients with sepsis[J]. Crit Care, 2023, 27(1):234.
[28] YU W K, MCNEIL J B, WICKERSHAM N E, et al. Angiopoietin-2 outperforms other endothelial biomarkers associated with severe acute kidney injury in patients with severe sepsis and respiratory failure[J]. Crit Care, 2021, 25(1):48.
[29] ATREYA M R, CVIJANOVICH N Z, FITZGERALD J C, et al. Prognostic and predictive value of endothelial dysfunction biomarkers in sepsis-associated acute kidney injury: risk-stratified analysis from a prospective observational cohort of pediatric septic shock[J]. Crit Care, 2023, 27(1):260.
[30] FANG Y, LI C, SHAO R, et al. The role of biomarkers of endothelial activation in predicting morbidity and morta-lity in patients with severe sepsis and septic shock in intensive care: A prospective observational study[J]. Thromb Res, 2018, 171:149-154.
[31] KIM W Y, KWEON O J, CHA M J, et al. Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: A preliminary pilot study[J]. PLoS One, 2021, 16(7):e0254167.
[32] KNAUP H, STAHL K, SCHMIDT B M W, et al. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers[J]. Crit Care, 2018, 22(1):285.
[33] HOFMAENNER D A, DAVID S. From Angiopoietin-2 to basic chemistry: differential effects of statins on endothelial homeostasis in ARDS[J]. Crit Care, 2023, 27(1):183.
[34] JIANG S, LI S, HU J, et al. Combined delivery of angiopoietin-1 gene and simvastatin mediated by anti-intercellular adhesion molecule-1 antibody-conjugated ternary nanoparticles for acute lung injury therapy[J]. Nanomedicine, 2019, 15(1):25-36.
[35] JONES R S, SMITH P S, BERG P H, et al. Efficacy and safety of LY3127804, an anti-angiopoietin-2 antibody, in a randomized, double-blind, placebo-controlled clinical trial in patients hospitalized with pneumonia and presumed or confirmed COVID-19[J]. Clin Med Insights Circ Respir Pulm Med, 2022, 16:11795484221119316.
Outlines

/